• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Hologic wins FDA clearance for COVID-flu-RSV assay

Hologic wins FDA clearance for COVID-flu-RSV assay

May 19, 2023 By Chris Newmarker

This Hologic marketing image for the Hologic-Panther-Fusion-SARS-CoV-2/Flu A/B/RSV-assay shows a gloved hand holding a sample over the Panther Fusion system.
The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay [Image courtesy of Hologic]
Hologic (Nasdaq: HOLX) today announced FDA 510(k) clearance of its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay.

The clearance comes after a winter in which the U.S. and other countries dealt with a “tripledemic” of COVID-19, influenza, and RSV. In February, the FDA granted an emergency use authorization for a COVID/flu/RSV test from BD.

“This past winter, we saw several respiratory illnesses — COVID, flu and RSV — spreading simultaneously throughout communities and often presenting with similar symptoms, making diagnoses difficult,” Hologic Diagnostic Solutions President Jennifer Schneiders said in a news release.

“While we are out of the respiratory virus season this year, accurate viral diagnosis remains a high priority for clinicians for the upcoming respiratory season, and we are committed to advancing COVID and respiratory diagnostics on our Panther Fusion system. This test will be a critical tool to help determine which respiratory virus or coinfection patients have so that providers can better inform the best course of treatment.”

The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay runs on Hologic’s fully automated, high-throughput Panther Fusion system. Panther Fusion can provide initial results in roughly three hours, with the ability to process more than 1,000 tests in 24 hours.

The flexible approach of this system, along with Hologic’s respiratory virus menu, offers various testing options from a single sample and allows healthcare professionals and laboratories to personalize patient testing based on medical history and local prevalence, according to Hologic.

The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay launches with the new RespDirect collection kit. RespDirect enables laboratories to directly load samples for processing on the Panther Fusion system without any uncapping or specimen transfer steps. Hologic says this design improvement saves time and reduces the potential for error repetitive stress injuries and exposure to viruses.

The U.S. Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority funded much of the project behind the new assay. The contract number was 75A50121P00022.

Hologic has shipped more than 200 million SARS-CoV-2 laboratory diagnostic tests worldwide since the onset of the COVID-19 pandemic.

Filed Under: 510(k), Diagnostics, Featured, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: COVID-19, Hologic

More recent news

  • AiM Medical Robotics’ $2M NIH grant and other extra medtech news
  • Intuitive draws on data from 14M cases to back da Vinci systems
  • Ropca wins FDA clearance for ultrasound automation systems
  • Zimmer Biomet lets go of former Nevro CEO amid leadership restructuring
  • Petal Surgical says its first-in-human incisionless surgery is coming soon and offers a first glimpse of its system

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy